Projects & Publications

Oncology Outcomes

Oncology Outcomes (O2), a highly experienced resource group dedicated to real-world evidence data generation and integration. Through this collaboration, Roche and O2 will work together to increase RWD acceptability and accessibility across the Canadian ecosystem.


The GeneSolve Study examines the value of genomic sequencing for diagnosing childhood rare diseases. Through a cross-institutional collaboration with Oxford University, PACER is developing new ways to address the high levels of uncertainty introduced by multi-omics technologies. This multi-country approach to economic analyses will support the timely and appropriate adoption of genomics for better diagnosing and treating children with rare diseases across jurisdictions.


The Center for Translational and Policy Research on Precision Medicine (TRANSPERS) is the premier research organization for developing evidence-based information about the use of precision medicine.

Related Publications

  • O'Brien G, Christensen KD, Sullivan HK, Stout NK, Diller L, Yeh JM, Wu AC. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 Oct 1;4(10):e2129742. doi: 10.1001/jamanetworkopen.2021.29742. PMID: 34661666.

  • Witteman HO, Ndjaboue R, Vaisson G, Dansokho SC, Arnold B, Bridges JFP, Comeau S, Fagerlin A, Gavaruzzi T, Marcoux M, Pieterse A, Pignone M, Provencher T, Racine C, Regier D, Rochefort-Brihay C, Thokala P, Weernink M, White DB, Wills CE, Jansen J. Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis. Med Decis Making. 2021 Oct;41(7):801-820. doi: 10.1177/0272989X211037946. PMID: 34565196; PMCID: PMC8482297.

  • O'Brien G, Christensen KD, Sullivan HK, Stout NK, Diller L, Yeh JM, Wu AC. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 Oct 1;4(10):e2129742. PMID: 34661666.

  • Chan KKW, Cheung MC, Regier DA, Hay A, Louie AV, Cheung WY, Tarride JE, Udayakumar S, Mittmann N. The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. Curr Oncol. 2021 Sep 21;28(5):3649-3658. doi: 10.3390/curroncol28050311. PMID: 34590616; PMCID: PMC8482104.

  • Mighton C, Clausen M, Sebastian A, Muir SM, Shickh S, Baxter NN, Scheer A, Glogowski E, Schrader KA, Thorpe KE, Kim THM, Lerner-Ellis J, Kim RH, Regier DA, Bayoumi AM, Bombard Y. Patient and public preferences for being recontacted with updated genomic results: a mixed methods study. Hum Genet. 2021 Sep 18. doi: 10.1007/s00439-021-02366-0. Epub ahead of print. PMID: 34537903.

  • Weymann D, Laskin J, Jones SJM, Lim H, Renouf DJ, Roscoe R, Schrader KA, Sun S, Yip S, Marra MA, Regier DA. Matching methods in precision oncology: An introduction and illustrative example. Mol Genet Genomic Med. 2021 Jan;9(1):e1554. doi: 10.1002/mgg3.1554. Epub 2020 Nov 25. PMID: 33237632; PMCID: PMC7963415.

  • Morrell L, Buchanan J, Rees S, Barker RW, Wordsworth S. What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK. Pharmacoeconomics. 2021 Aug 19. doi: 10.1007/s40273-021-01067-w. Epub ahead of print. PMID: 34409564.

  • IJzerman MJ. Cost of colorectal cancer care: sufficient to inform cancer policy? Lancet Gastroenterol Hepatol. 2021 Sep;6(9):679-680. doi: 10.1016/S2468-1253(21)00177-1. Epub 2021 Jul 28. PMID: 34329625.

  • Christensen KD, Schonman EF, Robinson JO, Roberts JS, Diamond PM, Lee KB, Green RC, McGuire AL. Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients. NPJ Genom Med. 2021 Aug 24;6(1):72. doi: 10.1038/s41525-021-00236-2. PMID: 34429410.

  • Cernat A, Hayeems RZ, Ungar WJ. Cascade health service use in family members following genetic testing in children: a scoping literature review. Eur J Hum Genet. 2021 Aug 26. doi: 10.1038/s41431-021-00952-4. Epub ahead of print. PMID: 34446836.

  • Gonzalez Sepulveda JM, Johnson FR, Marshall DA. Incomplete information and irrelevant attributes in stated-preference values for health interventions. Health Econ. 2021 Jul 30. doi: 10.1002/hec.4406. Epub ahead of print. PMID: 34331384.

  • Degeling K., Pereira-Salgado A., Corcoran N.M., Boutros P.C., Kuhn P., IJzerman M.J. Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review. European Urology Open Science. 2021;27:77-87.

  • IJzerman MJ, de Boer J, Azad A, Degeling K, Geoghegan J, Hewitt C, Hollande F, Lee B, To YH, Tothill RW, Wright G, Tie J, Dawson SJ. Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. Diagnostics (Basel). 2021 Jan 11;11(1):103. PMID: 33440749.

  • Wu Y, Balasubramaniam S, Rius R, Thorburn DR, Christodoulou J, Goranitis I. Genomic sequencing for the diagnosis of childhood mitochondrial disorders: a health economic evaluation. Eur J Hum Genet. 2021 Jun 8. PMID: 34099885.

  • To YH, Degeling K, Kosmider S, Wong R, Lee M, Dunn C, Gard G, Jalali A, Wong V, IJzerman M, Gibbs P, Tie J. Circulating Tumour DNA as a Potential Cost-Effective Biomarker to Reduce Adjuvant Chemotherapy Overtreatment in Stage II Colorectal Cancer. Pharmacoeconomics. 2021 Jun 5. PMID: 34089503.

  • Weymann D, Pollard S, Chan B, Titmuss E, Bohm A, Laskin J, Jones SJM, Pleasance E, Nelson J, Fok A, Lim H, Karsan A, Renouf DJ, Schrader KA, Sun S, Yip S, Schaeffer DF, Marra MA, Regier DA. Clinical and cost outcomes following genomics-informed treatment for advanced cancers. Cancer Med. 2021 Jun 21. PMID: 34152087.

  • Downie L, Amor DJ, Halliday J, Lewis S, Martyn M, Goranitis I. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. Laryngoscope. 2020 Dec 31. doi: 10.1002/lary.29356. Epub ahead of print. PMID: 33382469.

  • Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, Koleva-Kolarova R, Tsiachristas A, Wordsworth S, Rutten-van Mölken M; HEcoPerMed Consortium. Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. Pharmacoeconomics. 2021 Apr 16. doi: 10.1007/s40273-021-01010-z. Epub ahead of print. PMID: 33860928.

  • Smith HS, McGuire AL, Wittenberg E, Lavelle TA. Family-level impact of genetic testing: integrating health economics and ethical, legal, and social implications. Per Med. 2021 May;18(3):209-212. doi: 10.2217/pme-2021-0016. Epub 2021 Mar 17. PMID: 33728981.

  • Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev Pharmacoecon Outcomes Res. 2021 May 6:1-11. doi: 10.1080/14737167.2021.1917385. Epub ahead of print. PMID: 33852815.

  • van de Ven M, Simons MJHG, Koffijberg H, Joore MA, IJzerman MJ, Retèl VP, van Harten WH. Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer. 2021 May 1;21(1):488. doi: 10.1186/s12885-021-08214-8. PMID: 33933021; PMCID: PMC8088550.

  • Simons M, van de Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalised oncology. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr 29. doi: 10.1080/14737167.2021.1917386. Epub ahead of print. PMID: 33910430.